​

Keros Therapeutics (KROS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Keros Therapeutics Revenue Highlights

Latest Revenue (Y)

$3.55M

Latest Revenue (Q)

$211.25M

Main Segment (Y)

License

Keros Therapeutics Revenue by Period

Keros Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$3.55M2250.99%
2023-12-31$151.00K100.00%
2022-12-31--100.00%
2021-12-31$20.10M100.00%
2020-12-31--100.00%
2019-12-31$10.00M-
2018-12-31$10.00M-

Keros Therapeutics generated $3.55M in revenue during NA 2024, up 2250.99% compared to the previous quarter, and up 35.50% compared to the same period a year ago.

Keros Therapeutics Revenue by Quarter

DateRevenueChange
2025-03-31$211.25M6844.31%
2024-12-31$3.04M684.02%
2024-09-30$388.00K948.65%
2024-06-30$37.00K-55.42%
2024-03-31$83.00K-41.96%
2023-12-31$143.00K1687.50%
2023-09-30$8.00K100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30--100.00%
2022-06-30$100.00K100.00%
2022-03-31--100.00%
2021-12-31$20.00M100.00%
2021-09-30--100.00%
2021-06-30$100.00K100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--100.00%
2019-12-31$2.50M-
2019-09-30$2.50M-
2019-06-30$2.50M-
2019-03-31$2.50M-

Keros Therapeutics generated $211.25M in revenue during Q1 2025, up 6844.31% compared to the previous quarter, and up 147724.48% compared to the same period a year ago.

Keros Therapeutics Revenue Breakdown

Keros Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 22Dec 21
Service$3.00M--
License$144.00M$144.00M$144.00M

Keros Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: License (97.96%), and Service (2.04%).

Quarterly Revenue by Product

Product/ServiceJun 25Mar 25Dec 24Sep 24Mar 24Jun 23Mar 23Sep 22Jun 22Mar 22Dec 21Sep 21
Service, Other$18.17M$15.89M$83.00K---------
License-$195.35M$144.00M$144.00M$144.00M$144.00M$18.00M$20.00M$100.00K---
Service--$2.60M$400.00K--------

Keros Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Service, Other (100.00%).

Keros Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ZNTLZentalis Pharmaceuticals$67.42M-
KYMRKymera Therapeutics$47.07M$11.48M
MRUSMerus$36.13M$8.83M
KROSKeros Therapeutics$3.55M$211.25M
CRNXCrinetics Pharmaceuticals$1.04M$361.00K
INBXInhibrx Biosciences$200.00K-
PCVXVaxcyte--
LYELLyell Immunopharma-$8.00K
ORICORIC Pharmaceuticals--

KROS Revenue FAQ

What is Keros Therapeutics’s yearly revenue?

Keros Therapeutics's yearly revenue for 2024 was $3.55M, representing an increase of 2250.99% compared to 2023. The company's yearly revenue for 2023 was $151K, representing an increase of 100.00% compared to 2022. KROS's yearly revenue for 2022 was $0, representing a decrease of -100.00% compared to 2021.

What is Keros Therapeutics’s quarterly revenue?

Keros Therapeutics's quarterly revenue for Q1 2025 was $211.25M, a 6844.31% increase from the previous quarter (Q4 2024), and a 254413.25% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $3.04M, a 684.02% increase from the previous quarter (Q3 2024), and a 2027.27% increase year-over-year (Q4 2023). KROS's quarterly revenue for Q3 2024 was $388K, a 948.65% increase from the previous quarter (Q2 2024), and a 4750.00% increase year-over-year (Q3 2023).

What is Keros Therapeutics’s revenue growth rate?

Keros Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was 0%.

What are Keros Therapeutics’s revenue streams?

Keros Therapeutics's revenue streams in c 24 are Service, and License. Service generated $3M in revenue, accounting 2.04% of the company's total revenue License generated $144M in revenue, accounting 97.96% of the company's total revenue

What is Keros Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Keros Therapeutics was License. This segment made a revenue of $144M, representing 97.96% of the company's total revenue.